HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager patientINFORMation Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin, C. L. Articles by Feldman, E. L. Search for Related Content PubMed PubMed Citation Articles by Martin, C. L. Articles by Feldman, E. L. Social Bookmarking                What's this?

Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial Completion

Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Intervention and Complications (EDIC) Research Group

Address correspondence and reprint requests to the DCCT/EDIC Research Group, Box DCCT/EDIC Bethesda, MD 20892. E-mail: cleary{at}biostat.bsc.gwu.edu

OBJECTIVE—To evaluate the impact of prior intensive diabetes therapy on neuropathy among former Diabetes Control and Complications Trial (DCCT) participants.

RESEARCH DESIGN AND METHODS—At the conclusion of the DCCT, subjects in the intensive group were encouraged to maintain intensive therapy, and subjects in the conventional group were encouraged to begin intensive therapy. Thereafter, we annually assessed neuropathy as part of the Epidemiology of Diabetes Intervention and Complications (EDIC) study. Neuropathy was defined using the Michigan Neuropathy Screening Instrument (MNSI). We recorded potential adverse consequences of neuropathy.

RESULTS—At the first EDIC examination, 1,257 subjects participated in the neuropathy assessment. Consistent with DCCT results, the former intensive group showed a lower prevalence of neuropathy than the conventional group based on positive questionnaire (1.8 vs. 4.7%; P = 0.003) or examination (17.8 vs. 28.0%; P < 0.0001) results. Despite similar levels of glycemic control, symptoms and signs of neuropathy remained less prevalent among the former intensive group compared with the conventional group. At the beginning of the EDIC study, prior intensive therapy reduced the odds of having symptoms and signs of neuropathy using MNSI criteria by 64% (P = 0.0044) and 45% (P < 0.0001), respectively, with similar odds reductions observed for both neuropathic symptoms (51%, P < 0.0001) and neuropathic signs (43%, P < 0.0001) across 8 years of EDIC follow-up.

CONCLUSIONS—The benefits of 6.5 years of intensive therapy on neuropathy status extended for at least 8 years beyond the end of the DCCT, similar to the findings described for diabetic retinopathy and nephropathy.

Abbreviations: DCCT, Diabetes Control and Complications Trial • EDIC, Epidemiology of Diabetes Intervention and Complications • MNSI, Michigan Neuropathy Screening Instrument

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Find additional patient-related information at:

Strict Blood Glucose Control Helps Prevent Nerve Damage in People With Diabetes

This article has been cited by other articles:

				D. Ziegler Treatment of Diabetic Neuropathy and Neuropathic Pain: How far have we come? Diabetes Care, February 1, 2008; 31(Supplement_2): S255 - S261. [Abstract] [Full Text] [PDF]

				American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]

				S. Tesfaye, R. Tandan, E. J. Bastyr III, K. A. Kles, V. Skljarevski, K. L. Price, and for the Ruboxistaurin Study Group Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials Diabetes Care, October 1, 2007; 30(10): 2626 - 2632. [Abstract] [Full Text] [PDF]

				J. W. Albers, W. H. Herman, R. Pop-Busui, C. L. Martin, P. Cleary, B. Waberski, and for the Diabetes Control and Complications Trial ( Subclinical Neuropathy Among Diabetes Control and Complications Trial Participants Without Diagnosable Neuropathy at Trial Completion: Possible predictors of incident neuropathy? Diabetes Care, October 1, 2007; 30(10): 2613 - 2618. [Abstract] [Full Text] [PDF]

				G. S. Eisenbarth Update in Type 1 Diabetes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2403 - 2407. [Abstract] [Full Text] [PDF]

				M. M. Huizinga and A. Peltier Painful Diabetic Neuropathy: A Management-Centered Review Clin. Diabetes, January 1, 2007; 25(1): 6 - 15. [Abstract] [Full Text] [PDF]

				D. ZIEGLER Treatment of Diabetic Polyneuropathy: Update 2006 Ann. N.Y. Acad. Sci., November 1, 2006; 1084(1): 250 - 266. [Abstract] [Full Text] [PDF]

				L. SIBAL, H. N. LAW, J. GEBBIE, and P. HOME Cardiovascular Risk Factors Predicting the Development of Distal Symmetrical Polyneuropathy in People with Type 1 Diabetes: A 9-Year Follow-up Study Ann. N.Y. Acad. Sci., November 1, 2006; 1084(1): 304 - 318. [Abstract] [Full Text] [PDF]

				S. M Marshall and A. Flyvbjerg Prevention and early detection of vascular complications of diabetes. BMJ, September 2, 2006; 333(7566): 475 - 480. [Full Text] [PDF]

				D. A. Antonetti, A. J. Barber, S. K. Bronson, W. M. Freeman, T. W. Gardner, L. S. Jefferson, M. Kester, S. R. Kimball, J. K. Krady, K. F. LaNoue, et al. Diabetic Retinopathy: Seeing Beyond Glucose-Induced Microvascular Disease Diabetes, September 1, 2006; 55(9): 2401 - 2411. [Abstract] [Full Text] [PDF]

				Endocrinology & Metabolism News March 2006 J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 17a - 17a. [Full Text] [PDF]